-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★Oncolytic virus events: A new journey of tumor immunityYimai new observations ★The commercialization process of China's CAR-T cell therapy: large-scale purification of viral vectorsYimai Meng broke the news.
Click on the picture and sign up immediately for 2021 July 14/eMedClub News/--Recently, Caribou Biosciences announced that it has been the first B-cell non-Hodgkin lymphoma in the Phase 1 clinical trial of the main candidate product CB-010 for CAR-T cell therapy.
The patient is administered
.
Caribou was co-founded by Nobel Laureate Professor Jennifer Doudna, aiming to use RNA-DNA hybrid sequence-mediated CRISPR gene editing system (chRDNA) to develop allogeneic cell therapy with potentially transformative effects on patients
.
It is worth mentioning that Intellia Therapeutics, a CRISPR gene editing company founded by Jennifer Doudna, has also recently achieved a major milestone.
On June 26, Intellia announced the world's first clinical trial results of CRISPR gene editing therapy in an individual
.
Recommended reading: Heavy! The results of the first clinical trial of CRISPR gene editing in vivo have been announcedYimai Meng broke the news that gene editing technology helps CAR-T cell therapy CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells
.
These T cells have been engineered using Caribou's chRDNA technology to specifically integrate CD19-CAR sites into the T cell genome at the TRAC site, thereby eliminating the expression of T cell receptors and reducing graft resistance.
The risk of host disease (GvHD)
.
At the same time, chRDNA was used to further modify cells and knock out the gene encoding PD-1 to inhibit the expression of PD-1 protein on the surface of CAR-T cells
.
The purpose of eliminating PD-1 expression is to improve the durability of CAR-T cell anti-tumor activity by reducing CB-010 depletion, so as to obtain a better therapeutic index compared with other allogeneic CAR-T cells
.
"Pushing our first allogeneic CAR-T cell therapy to the clinic is an important milestone for Caribou," said Dr.
Rachel Haurwitz, President and CEO of Caribou.
"Using our proprietary chRDNA CRISPR technology, we developed A series of ready-made CAR-T and CAR-NK cell therapies, compared with autologous methods, it is possible to provide services to more patients
.
We believe that improving cell persistence is the key to unlocking the full potential of these therapies
.
Through CB -010, we are evaluating the potential persistence enhancement effect of removing PD-1 protein from the surface of these CD19-targeted CAR-T cells
.
"▲ Dr.
Rachel Haurwitz, President and CEO of Caribou (Source: Reference 2) Caribou will now To evaluate the safety and tolerability of CB-010 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma in a phase 1 clinical trial, and determine the dose level for the expansion phase of the study, which is expected to be available in early 2022 Preliminary data from this clinical trial
.
Caribou is a clinical-stage CRISPR genome editing biopharmaceutical company, committed to changing the lives of patients suffering from devastating diseases by applying the company's proprietary chRDNA technology to the development of next-generation genome editing cell therapies
.
The company is developing a series of genome editing, ready-made CAR-T and CAR-NK cell therapies for the treatment of hematological malignancies and solid tumors
.
Caribou currently has a number of cancer cell therapies under investigation, and the most advanced research is CB-101
.
Its second project, CB-011, is a CAR-T that targets BCMA in the treatment of multiple myeloma
.
The target of the third study, CB-012, is a CAR-T targeting CD371 for the treatment of acute myeloid leukemia.
It is still in the preclinical development stage
.
The company is customizing these three plans for patients whose cancer recurs despite other treatments or who initially did not respond to these treatments
.
In addition, Caribou also has a CAR-NK cell therapy called CB-020, which is used to treat solid tumors.
The treatment targets and other information have not been disclosed
.
▲Caribou R&D pipeline (picture source: Caribou) Reference materials: 1.
https:// -trial-evaluating-cb-010-a-crispr-edited-allogeneic-anti-cd19-car-t-cell-therapy-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma /2.
https://fortune.
com/40-under-40/2016/rachel-haurwitz/ Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, industry insights, etc.
of bio-innovative drugs, and is a high-end matrix user of all media Up to 160,000+, of which industrial users accounted for over 50%, scientific research and clinical users accounted for about 30%, and investment institutions accounted for more than 5%
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
Click on the picture and sign up immediately for 2021 July 14/eMedClub News/--Recently, Caribou Biosciences announced that it has been the first B-cell non-Hodgkin lymphoma in the Phase 1 clinical trial of the main candidate product CB-010 for CAR-T cell therapy.
The patient is administered
.
Caribou was co-founded by Nobel Laureate Professor Jennifer Doudna, aiming to use RNA-DNA hybrid sequence-mediated CRISPR gene editing system (chRDNA) to develop allogeneic cell therapy with potentially transformative effects on patients
.
It is worth mentioning that Intellia Therapeutics, a CRISPR gene editing company founded by Jennifer Doudna, has also recently achieved a major milestone.
On June 26, Intellia announced the world's first clinical trial results of CRISPR gene editing therapy in an individual
.
Recommended reading: Heavy! The results of the first clinical trial of CRISPR gene editing in vivo have been announcedYimai Meng broke the news that gene editing technology helps CAR-T cell therapy CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells
.
These T cells have been engineered using Caribou's chRDNA technology to specifically integrate CD19-CAR sites into the T cell genome at the TRAC site, thereby eliminating the expression of T cell receptors and reducing graft resistance.
The risk of host disease (GvHD)
.
At the same time, chRDNA was used to further modify cells and knock out the gene encoding PD-1 to inhibit the expression of PD-1 protein on the surface of CAR-T cells
.
The purpose of eliminating PD-1 expression is to improve the durability of CAR-T cell anti-tumor activity by reducing CB-010 depletion, so as to obtain a better therapeutic index compared with other allogeneic CAR-T cells
.
"Pushing our first allogeneic CAR-T cell therapy to the clinic is an important milestone for Caribou," said Dr.
Rachel Haurwitz, President and CEO of Caribou.
"Using our proprietary chRDNA CRISPR technology, we developed A series of ready-made CAR-T and CAR-NK cell therapies, compared with autologous methods, it is possible to provide services to more patients
.
We believe that improving cell persistence is the key to unlocking the full potential of these therapies
.
Through CB -010, we are evaluating the potential persistence enhancement effect of removing PD-1 protein from the surface of these CD19-targeted CAR-T cells
.
"▲ Dr.
Rachel Haurwitz, President and CEO of Caribou (Source: Reference 2) Caribou will now To evaluate the safety and tolerability of CB-010 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma in a phase 1 clinical trial, and determine the dose level for the expansion phase of the study, which is expected to be available in early 2022 Preliminary data from this clinical trial
.
Caribou is a clinical-stage CRISPR genome editing biopharmaceutical company, committed to changing the lives of patients suffering from devastating diseases by applying the company's proprietary chRDNA technology to the development of next-generation genome editing cell therapies
.
The company is developing a series of genome editing, ready-made CAR-T and CAR-NK cell therapies for the treatment of hematological malignancies and solid tumors
.
Caribou currently has a number of cancer cell therapies under investigation, and the most advanced research is CB-101
.
Its second project, CB-011, is a CAR-T that targets BCMA in the treatment of multiple myeloma
.
The target of the third study, CB-012, is a CAR-T targeting CD371 for the treatment of acute myeloid leukemia.
It is still in the preclinical development stage
.
The company is customizing these three plans for patients whose cancer recurs despite other treatments or who initially did not respond to these treatments
.
In addition, Caribou also has a CAR-NK cell therapy called CB-020, which is used to treat solid tumors.
The treatment targets and other information have not been disclosed
.
▲Caribou R&D pipeline (picture source: Caribou) Reference materials: 1.
https:// -trial-evaluating-cb-010-a-crispr-edited-allogeneic-anti-cd19-car-t-cell-therapy-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma /2.
https://fortune.
com/40-under-40/2016/rachel-haurwitz/ Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, industry insights, etc.
of bio-innovative drugs, and is a high-end matrix user of all media Up to 160,000+, of which industrial users accounted for over 50%, scientific research and clinical users accounted for about 30%, and investment institutions accounted for more than 5%
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
